Is Desh Rakshak overvalued or undervalued?

As of 17 November 2025, the valuation grade for Desh Rakshak has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 33.81, an EV to EBITDA of 13.66, and a ROCE of 7.79%. In comparison, its peers show a range of valuations, with Sun Pharma at a PE of 36.69 and an EV to EBITDA of 24.22, while Cipla is more attractively valued at a PE of 22.81 and an EV to EBITDA of 16.14.
Despite the recent stock performance showing a significant year-to-date return of 136.33% compared to the Sensex's 8.72%, the current valuation metrics suggest that Desh Rakshak is not undervalued but rather fairly positioned in the market. The company's PEG ratio stands at 0.00, which may indicate growth expectations are not being priced in, yet the overall valuation suggests that it is not a compelling buy at this time.